Clicky

Pear Therapeutics, Inc.(PEAR)

Description: Pear Therapeutics, Inc., which is traded on Nasdaq as PEAR, is the parent company of Pear Therapeutics (US), Inc. Pear is the leader in developing and commercializing software-based medicines, called prescription digital therapeutics (PDTs). Pear aims to redefine care through the widespread use of clinically validated software-based therapeutics to provide better outcomes for patients, smarter engagement and tracking tools for clinicians, and cost-effective solutions for payers. Pear has the first end-to-end platform to discover, develop, and deliver PDTs to patients and a pipeline of products and product candidates across therapeutic areas, including the first three PDTs with disease treatment claims from the FDA. Pear’s product, reSET®, for the treatment of substance use disorder, was the first PDT to receive marketing authorization from the FDA to treat disease. Pear’s second product, reSET-O®, for the treatment of opioid use disorder, was the first PDT to receive Breakthrough Designation. Pear’s third product, Somryst® for the treatment of chronic insomnia, was the first PDT submitted through FDA’s traditional 510(k) pathway while simultaneously reviewed through FDA’s Software Precertification Pilot Program.


Keywords: Disease FDA Opioid Use Disorder Substance Dependence Digital Therapeutics Substance Use Disorder Treatment Of Substance Use Disorder

Home Page: peartherapeutics.com

PEAR Technical Analysis

200 State Street
Boston, MA 02109
United States
Phone: 617 925 7848


Officers

Name Title
Dr. Corey M. McCann M.D., Ph.D. Founder, Pres, CEO & Director
Mr. Christopher D. T. Guiffre J.D., M.B.A., MBA CFO, COO, Treasurer & Assistant Sec.
Ms. Julia M. Strandberg M.B.A. Chief Commercial Officer
Mr. Ronan P. O'Brien J.D. Chief Compliance Officer, Gen. Counsel & Sec.
Ms. Meara Murphy Sr. Director of Corp. Communications
Dr. Yuri Maricich M.B.A., M.D. Chief Medical Officer & Head of Devel.
Mr. Chris Valosky M.B.A. VP of Sales
Ms. Katherine Jeffery M.Sc. Chief People Officer
Ms. Erin K. Brenner Chief Product Devel. Officer
Ms. Ellen E. Snow CPA, CGMA VP & Corp. Controller

Exchange: NASDAQ

Country: US

Currency: US Dollar ($)

Forward PE: 0
Trailing PE: 0
Price-to-Book MRQ: 4.7008
Price-to-Sales TTM: 21.695
IPO Date: 2021-03-31
Fiscal Year End: December
Full Time Employees: 260
Back to stocks